Type 1 Diabetes TrialNet
Study Participants Healthcare Professionals Researchers Locations Publications What is TrialNet? News and Events Get Involved! Home
Information for Study Participants

TrialNet Studies

TrialNet mainly conducts two types of studies:

Studies for people who do not have type 1 diabetes, but are at increased risk because they have a family member with the disease:

Study Status Description
The Natural History Study of the Development of Type 1 Diabetes Recruiting This study screens and observes relatives of people with type 1 diabetes to learn more about how the disease occurs
The Oral Insulin for Prevention of Type 1 Diabetes Study Recruiting This study tests whether a daily oral insulin capsule can prevent or delay the disease in at-risk relatives of people with type 1 diabetes
The Nutritional Intervention to Prevent Type 1 Diabetes Study No Longer Recruiting A pilot study testing whether docosahexaenoic acid (DHA), and omega-3 fatty acid found in some foods can prevent or delay the autoimmunity leading to type 1 diabetes

 

Studies for those recently diagnosed with type 1 diabetes (within 100 days

Study Status Description
CTLA-4 Ig (Abatacept) in Recent Onset Diabetes Recruiting Currently testing the drug abatacept, which is already being used to treat rheumatoid arthritis, to try to protect remaining insulin production
GAD in New Onset Type 1 Diabetes Coming Soon This study will explore whether treatment with multiple injections of the GAD protein can help preserve insulin production.
Metabolic Control in New Onset Diabetes Coming Soon This study will look at whether early intensive glucose control can help preserve insulin production.
The Rituximab Study (Anti-CD20) No Longer Recruiting This study is trying to see if it is possible to stop or slow down the immune system's attack in newly diagnosed type 1 diabetes patients so that the remaining beta cells can survive and keep making some of the insulin your body needs.
The MMF/DZB Study No Longer Recruiting This study will examine whether a combination of two medicines can stop the immune system from destroying beta cells in new onset type 1 diabetes patients (within 3 months of diagnosis).

 

Type 1 Diabetes TrialNet is collaborating with the following NIH-funded groups, also conducting type 1 diabetes research:

Study Status Description
T1DGC Recruiting

The Type 1 Diabetes Genetics Consortium (T1DGC) is collecting blood samples and health information from African American and Mexican American individuals with type 1 diabetes, as well as from people who do not have type 1 or type 2 diabetes in their immediate family.

For more information, visit (www.t1dgc.org)


The Immune Tolerance Network is offering additional intervention studies. More information is available at www.immunetolerance.org.